FY2026 EPS Estimates for UTHR Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings per share (EPS) estimate for United Therapeutics from $31.44 to $31.56, maintaining an "Overweight" rating on the stock with a target price of $525.00.
• Other analysts have also increased their price targets for United Therapeutics, with HC Wainwright raising it to $500.00 and UBS Group to $560.00, reflecting a generally positive outlook on the stock.
• Insider selling activity has been notable, with COO Michael Benkowitz selling 22,500 shares and CEO Martine A. Rothblatt selling 8,000 shares recently, indicating a significant reduction in their ownership stake in the company.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2026 earnings per share (EPS) estimates for shares of United Therapeutics in a report issued on Wednesday, September 10th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will earn $31.56 per share for the year, up from their previous estimate of $31.44. Cantor Fitzgerald currently has a "Overweight" rating and a $525.00 target price on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

A number of other analysts have also commented on UTHR. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Bank of America lifted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. Finally, Morgan Stanley decreased their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $438.85.

United Therapeutics Stock Performance

Shares of UTHR opened at $396.50 on Thursday. The stock has a market capitalization of $17.89 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 6.16 and a beta of 0.62. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $436.95. The stock has a fifty day moving average of $314.12 and a 200-day moving average of $306.91.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the firm posted $5.85 EPS.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers lifted its holdings in shares of United Therapeutics by 5.6% in the fourth quarter. Cetera Investment Advisers now owns 8,715 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 463 shares in the last quarter. Ethic Inc. purchased a new position in United Therapeutics in the fourth quarter worth $959,000. Focus Partners Wealth grew its stake in United Therapeutics by 127.1% in the 4th quarter. Focus Partners Wealth now owns 1,917 shares of the biotechnology company's stock valued at $679,000 after purchasing an additional 1,073 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of United Therapeutics by 26.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,446 shares of the biotechnology company's stock valued at $2,281,000 after purchasing an additional 1,342 shares during the last quarter. Finally, Nomura Holdings Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth $2,090,000. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total value of $3,188,400.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company's stock, valued at approximately $51,811.50. This represents a 98.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,816 shares of company stock valued at $44,247,193 over the last ninety days. 10.30% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.